KalVista Pharmaceuticals, Inc.
KALV
$13.31
$0.100.76%
NASDAQ
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 26.18% | -24.18% | |||
| Gross Profit | -26.18% | 24.18% | |||
| SG&A Expenses | 28.98% | 3.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 28.16% | -6.27% | |||
| Operating Income | -28.16% | 6.27% | |||
| Income Before Tax | -19.92% | -4.72% | |||
| Income Tax Expenses | -120.13% | -- | |||
| Earnings from Continuing Operations | -7.66% | -14.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.66% | -14.77% | |||
| EBIT | -28.16% | 6.27% | |||
| EBITDA | -28.23% | 6.30% | |||
| EPS Basic | -6.85% | -1.80% | |||
| Normalized Basic EPS | -19.24% | 8.04% | |||
| EPS Diluted | -6.85% | -1.80% | |||
| Normalized Diluted EPS | -19.24% | 8.04% | |||
| Average Basic Shares Outstanding | 0.77% | 12.73% | |||
| Average Diluted Shares Outstanding | 0.77% | 12.73% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||